Cagrilintide + Semaglutide 10mg Blend
Components: Cagrilintide + Semaglutide
A dual GLP-1/amylin analogue weight loss blend combining Cagrilintide (5mg) and Semaglutide (5mg) in a 10mg vial. Mirrors the CagriSema mechanism studied in clinical trials for obesity treatment.
Blend Composition
This is a single pre-mixed vial — one reconstitution for all components.
Synergy Explanation
Semaglutide activates GLP-1 receptors to suppress appetite, slow gastric emptying, and improve glycemic control. Cagrilintide is a long-acting amylin analogue that provides complementary satiety signaling through the amylin receptor. The combination (CagriSema) addresses two independent satiety axes, producing greater weight loss than either agent alone in clinical research.
Reconstitution Guide
-
Allow the vial to reach room temperature for 5 minutes before handling.
-
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
-
Sterilize the vial stopper with an alcohol swab and allow to dry.
-
Inject the BAC water slowly down the inside wall of the vial.
-
Gently swirl or roll until fully dissolved. Do not shake.
-
Label with reconstitution date and store refrigerated at 2u20138 u00b0C (35.6u201346.4 u00b0F).
Always use bacteriostatic water — not sterile water — to extend shelf life of your reconstituted blend.
Dosage Protocols
| Protocol | Dose | Frequency | Duration | Route | Notes |
|---|---|---|---|---|---|
| Weekly Titration Protocol | 250 mcg each (Cagrilintide + Semaglutide) starting dose, titrating to 2400 mcg each | Once weekly | 16u201320 weeks | SubQ | Begin at 250 mcg each per week. Increase gradually every 4 weeks as tolerated. Maximum studied dose is 2400 mcg each per week. GI side effects are most pronounced in the first 4u20138 weeks. |
Storage Instructions
Lyophilized (Dry)
Store at ≤−15 °C (5 °F). For long-term storage, ≤−50 °C (−58 °F) preferred.
Reconstituted
Refrigerate at 2–8 °C (35.6–46.4 °F). Use within 3–4 weeks. Do not freeze after reconstitution.
Keep the reconstituted vial refrigerated at all times. Protect from light.
Supplies Needed
-
Bacteriostatic water (BAC water) 10 mL vial
-
Insulin syringes (U-100) 0.5 mL, 29u201331 gauge
-
Alcohol swabs For stopper and injection site sterilization
Potential Side Effects
Nausea, vomiting, and GI discomfort (especially during titration). Decreased appetite (expected mechanism). Injection site reactions. Both agents are long-acting; side effects can persist for days after administration.
Questions about Cagrilintide + Semaglutide 10mg Blend
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. It activates amylin receptors to suppress appetite and reduce food intake through a mechanism distinct from GLP-1. In clinical trials (SCALE CROWN), CagriSema produced significantly greater weight loss than either compound alone.
Once weekly subcutaneous injection, consistent with the half-lives of both Cagrilintide and Semaglutide.
Research Use Disclaimer
This content is for educational purposes only and does not constitute medical advice. For research use only.